A Phase 2 Open-Label 2-Cohort Study of INCB050465 a PI3Kd Inhibitor in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)
Brief description of study
If you have been diagnosed with relapsed or refractory marginal zone lymphoma (a subtype of Non-Hodgkin's Lymphoma), you may qualify to participate in a clinical trial. The main goal of this phase 2 study is to determine the effectiveness of the experimental drug, INCB050465, in patients with marginal zone lymphoma. In addition, we would like to study skin, stool, and blood samples to understand potential predictive biological markers associated with safety, how well you respond, or resist treatment over time.
Clinical Study Identifier: s17-00726
ClinicalTrials.gov Identifier: NCTs17-00726
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
